AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04001582 — intervention group
Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their condition.
Study NCT01788969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: Agent + training vs Placebo + training
Study NCT01788969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Agent + training vs Placebo + training
Study NCT04216953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults
Study NCT04216953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 20-mL glass vial containing 1200 mg of atezolizumab.
Study NCT02837250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pos4Health
Description: This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
Study NCT02837250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
Study NCT02596009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breezhaler®
Description: No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
Study NCT02596009 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ellipta®
Description: No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
Study NCT02596009 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Handihaler®
Description: No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
Study NCT03669627 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: aTIV Primer
Description: MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
Study NCT03669627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aTIV Primer
Description: MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
Study NCT03669627 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: QIV Primer
Description: Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
Study NCT03669627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aTIV Booster
Description: MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
Study NCT03669627 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV Booster
Description: Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
Study NCT03669627 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: QIV Booster
Description: Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
Study NCT00702130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: pravastatin 40mg per os once daily
Study NCT01018459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.
Study NCT01018459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
Study NCT00545831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolidine
Description: 2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
Study NCT00545831 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic Serum
Description: 2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
Study NCT01650181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients with Steatohepatitis treated with diet, exercise and metformin
Study NCT01650181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Siliphos+ Selenium - Methionine + Alpha Lipoic Acid
Description: Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
Study NCT01650181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Siliphos+ Selenium - Methionine + Alpha Lipoic Acid
Description: Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
Study NCT01650181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients with fatty liver treated with diet, exercise and metformin
Study NCT00559962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733
Description: 3 capsules each evening for each 4-week period
Study NCT00559962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 capsules each evening for each 4-week period
Study NCT00717808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranilast
Description: Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
Study NCT00717808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
Study NCT01495793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied.
Study NCT01327066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 600 mg, single oral dose
Study NCT01327066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 2000 mg, single oral dose
Study NCT01327066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg, single oral dose
Study NCT01327066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg, single oral dose
Study NCT01327066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Droxidopa or Moxifloxacin
Study NCT03302221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine paravertebral block
Description: The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
Study NCT03302221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine epidural block
Description: A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
Study NCT03302221 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.5% ropivacaine local anaesthesia
Description: local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
Study NCT02769182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring and training using the system
Description: subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
Study NCT02769182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
Study NCT01694927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
Study NCT02057224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation using Medtronic Symplicity System (mono-electrode)
Description: Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
Study NCT00953017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miralax (PEG 3350)
Description: Miralax 255gm bottle
Study NCT00559962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733 and atorvastatin
Description: 3 capsules each evening for each 4-week period
Study NCT00559962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733 and fenofibrate
Description: 3 capsules each evening for each 4-week period
Study NCT00953017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitiza (Lubiprostone)
Description: Amitiza 24mcg gelcap
Study NCT00953017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulcolax (Bisacodyl)
Description: Bisacodyl 5mg tab x2
Study NCT00953017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely (polyethylene glycol)
Description: Golytely 1 gallon
Study NCT02350114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 Minute Walk Test
Description: Evaluation of walking distance on standardized 6 minute walk test
Study NCT00741026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg po qhs for 3 days
Description: (1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
Study NCT00559962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733 and ezetimibe
Description: 3 capsules each evening for each 4-week period
Study NCT00741026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
Study NCT03930524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Description: Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
Study NCT03930524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Monitoring (SM)
Description: Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
Study NCT03930524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-BASICS
Description: Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
Study NCT03930524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion Consultation
Description: A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
Study NCT03930524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-Bridge Online Health Coach
Description: A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
Study NCT03410979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737 single dose
Description: GLPG2737 oral suspension, single ascending doses
Study NCT03410979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Placebo, oral suspension.
Study NCT03410979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737 multiple dose
Description: GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
Study NCT03410979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG2737 multiple dose
Description: Placebo, oral suspension, daily for 14 days
Study NCT04330066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound measurement of the endometrial lining
Description: On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
Study NCT03514446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy duration for 7 days
Description: Antibiotic therapy for seven days
Study NCT02086734 — intervention group
Intervention type: OTHER
Intervention: Perfusion-CT
Description: 1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT
Study NCT01198327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
Study NCT01198327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Laser
Description: Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
Study NCT04485026 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local consolidative radiation therapy
Description: All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
Study NCT04485026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care radiation therapy
Description: Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
Study NCT00365326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Catheter-based intracoronary injection
Description: This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
Study NCT03145727 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
Study NCT03145727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency Group
Description: In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
Study NCT03145727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Group
Description: In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
Study NCT01657591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL888
Description: Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
Study NCT01657591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
Study NCT02098434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montreal Imaging Stress Task
Description: Math task developed to induce a stress response in a laboratory setting
Study NCT01738282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Study NCT01738282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for baclofen)